The main goal is to find out whether this approach can be carried out safely and whether participants can complete the treatment plan. Each participant will attend three sessions in which the medication is taken, and each session will be followed by a counseling period called an integration session to help process the experience. A final assessment will be performed about a week after the last integration session.

“Feasibility” means checking if the whole process can be done as planned, while “safety” means watching for any unwanted medical problems, known as adverse events. Integration sessions are meetings with a therapist to discuss thoughts and feelings that arise after taking the medication, helping to make sense of the experience. Throughout the study, health professionals will monitor participants for any side effects and will record whether anyone stops the treatment early.

The aim of the trial is to see whether the nitrous oxide mixture reduces PTSD symptoms more than the medical air mixture. Participants will attend four weekly sessions where the inhalation and story listening take place, and they will be evaluated before the first session, after the last session, and again three months later. Symptom changes will be measured using several questionnaires, including the clinician‑administered interview called CAPS-5, a self‑report checklist called PCL-5, a depression screen named PHQ-9, an anxiety rating called STAI, a dissociation questionnaire known as DES-28, and a brief assessment of daily functioning called FAST. Any side effects will be recorded throughout the study.

People who join the trial will be assigned by chance (randomized) to one of the two groups, and neither the participants nor the study staff will know which treatment is being given (double‑blind). The medication is given as a small injection under the skin (subcutaneous) using a pre‑filled syringe. After the first dose, participants will attend regular clinic visits for several weeks to monitor safety and track any changes in mood. The study will continue until enough participants have experienced a return of symptoms (relapse) to allow comparison of the two groups.

The purpose of the study is to see if the combination is safe, well‑tolerated, and practical to use. Participants will start with a low amount of Trazodone that is gradually increased over several visits. After the selected dose is reached, a fixed amount of psilocybin will be taken, and the person will be monitored for about a month. During this time, doctors will check vital signs such as heart rate and blood pressure, perform simple heart tests, and run laboratory checks. They will also ask participants about any changes in mood, thoughts of self‑harm, and how they feel during the psilocybin experience. The study will also look at pharmacokinetics, which means how the body absorbs, distributes, and clears both medicines.

Participants are randomly assigned to receive either the test drug or placebo for about three months, and neither the participants nor the study staff know which treatment is given, a design known as double-blind. After the initial 12‑week period, the study continues for an additional 40 weeks in a phase where participants may switch to other antipsychotic medications or continue the study drug, using a “double‑dummy” approach to keep the blind intact. Throughout the trial, safety checks and simple questionnaires are performed at regular visits to monitor how participants feel and whether any problems develop.

The purpose of the study is to evaluate the effect of psilocybin on symptoms of the disorder. Participants receive the medication under supervision, attend several therapy sessions over a period of weeks, and return for follow‑up visits to track any changes. The trial follows a randomised, triple‑blind design, meaning participants are assigned by chance and neither the participants, the clinicians, nor the data analysts know who receives the active medication or the active‑placebo, ensuring unbiased results.

The purpose of the trial is to find out whether adding pramipexole to the usual treatment can reduce anhedonia more effectively than placebo over a period of six weeks. Participants will be randomly assigned to receive either the active medication or the placebo, and neither the participants nor the study staff will know which is which (this is called a double‑blind design). Throughout the study, participants will visit the clinic several times for brief checks, and they will keep taking the tablets every day.

After the initial six‑week period, participants may be offered an open‑label follow‑up where everyone receives the active medication for up to 15 additional weeks. During the trial, simple tools such as questionnaires about mood and activity levels will be used, and some participants may undergo brain imaging with fMRI to explore how the drug affects brain activity. Safety will be monitored by asking about side effects and checking for any signs of mood changes.

Participants will take the study medication by mouth once a day for about two months. At the beginning and after the eight‑week period, they will complete the Oxford Depression Questionnaire (ODQ), a set of questions that measures how often different feelings are experienced. Additional questionnaires will ask about overall mood, thinking and memory (cognition), sleep quality, daily functioning at work, school, or home, and overall quality of life. The study follows a simple schedule of visits and questionnaire completion without any invasive procedures.

The purpose of the trial is to determine whether this combined therapy is safe and practical for this age group. Participants first undergo screening and baseline assessments, then attend a series of therapy sessions during which the medication is taken in capsule form. After the treatment phase, they continue with follow‑up visits to monitor any side effects and to observe changes in mood and daily functioning, while a separate group receives the same therapy at a later time for comparison.

The aim is to see whether the combination of the medication and psychotherapy leads to greater improvement in mood compared with the medication plus basic support or with the usual treatment that patients normally receive (standard of care). Volunteers will attend an initial screening, take the capsule in a comfortable setting, meet with a therapist for several sessions, and then return for regular check‑ins over the next year to monitor mood, sleep and overall well‑being. Terms such as “psychotherapy” refer to professional talk therapy that helps people process thoughts and feelings, while “basic support” means brief guidance without the full therapeutic program.

The purpose of the trial is to see whether adding the study drug to standard treatment leads to greater overall improvement in symptoms after six weeks. Volunteers are assigned to one of the two groups by chance in a double‑blind manner, meaning neither the participants nor the study staff know who receives the active substance. Over the six‑week period, participants will attend regular visits where simple questionnaires and brief health checks are completed to track changes in mood, anxiety, daily functioning, and overall quality of life. After the treatment phase, participants will have a final follow‑up visit to assess any lasting effects.

Participants will be assigned to one of two groups. In the first group, a dose of propranolol is taken orally before each of six weekly memory‑reactivation sessions. In the second group, participants attend eight weekly psychotherapy sessions without any medication. After the final session, researchers will check the participants’ symptoms a week later and then again at three and six months to see how the treatment worked over time. Throughout the study, any side effects or changes in mood, depression, or daily functioning will be recorded to evaluate safety and overall benefit.

The purpose of the trial is to find out if long‑term treatment with azetukalner is safe and can be tolerated without serious side effects. Participants will attend regular clinic visits where they will have basic health checks, give blood samples, and complete short questionnaires about how they feel. The study will continue for many months so researchers can observe any issues that might develop over time.

Besides safety, the study will track changes in mood and daily functioning using several common rating tools: the HAMD-17 score, which is a list of questions that measures how severe the depression is; the SHAPS score, which looks at the ability to feel pleasure; the CGI-S rating, a doctor’s overall impression of illness severity; the Q-LES-Q-SF survey, which asks about enjoyment of everyday life; and the SDS questionnaire, which checks how depression affects work, social activities, and home tasks. These measures help determine whether the medication improves or worsens the condition.

The main aim is to find out whether this combined approach is safe, practical, and helpful for veterans whose symptoms have not improved with other treatments.

During the trial, participants will attend several visits over a few months. After an initial screening, they will receive a low dose of the medication followed by a higher dose in separate sessions, each accompanied by a therapist. Between sessions, they will have regular follow‑up appointments to monitor health, discuss experiences, and complete questionnaires about symptoms, mood, and daily functioning.

The aim is to compare the effect of two larger doses given three weeks apart with two smaller doses given on the same schedule, to see which approach better prevents a return to heavy drinking after a period of detoxification. Participants will receive the assigned capsules, attend regular check‑in visits, and record their drinking using a calendar method that helps recall daily alcohol use.

During the six‑month follow‑up, researchers will note the first day a participant drinks a large amount (defined as at least 60 g of alcohol) and will collect information on mood, anxiety, and overall quality of life at several points. Blood samples will also be taken at the start and near the end of the study to monitor safety.

The purpose of the study is to evaluate the long‑term outcomes and safety of repeated adjuvant (additional) treatment with rituximab in this condition. Participants receive two infusions several weeks apart and are then followed for several months with regular clinic visits to check how they feel and to monitor any side effects.

During the follow‑up, doctors use simple rating scales such as the Clinical Global Impression – Improvement, which measures how much a person’s symptoms have gotten better, and the Clinical Global Impression – Severity, which rates how serious the illness is. Patients also complete short questionnaires about their overall health, daily functioning, and any changes in blood tests that may show immune system activity. Family members may be asked to give their view of any improvement as well.

Participants will take the study drug by mouth every day for several months, with regular visits to check for any side effects and to answer simple questionnaires. Researchers will monitor for any new health problems, serious problems, and specific symptoms related to the study drugs. They will also use a few rating tools to watch for movement‑related side effects and to assess thoughts of self‑harm, using the C-SSRS questionnaire and movement scales called the SAS, BARS, and AIMS. The study ends after the treatment period and a short follow‑up to confirm the safety findings.

Participants receive the spray once daily for four weeks. At the start and after 30 days, they undergo a brain scan called fMRI, which shows how certain brain areas are active. They also report their cravings at the beginning, after one week, and after four weeks, and their drug use is checked again at three and six months after the treatment period. The study looks at changes in cravings, brain activity, and how long participants stay away from drugs.

The purpose of the study is to evaluate the long‑term safety and tolerability of the medication. Over several months, participants will take the drug each day and attend regular clinic visits where doctors will check blood work (laboratory tests that look at how the body is functioning), perform an ECG (a quick test that records the heart’s electrical activity), measure vital signs such as blood pressure and weight, and conduct simple memory and thinking assessments to see how cognition changes.

Throughout the trial, any side effects or new health problems will be recorded, and participants may stop the medication if serious issues arise. The overall goal is to determine whether the drug can be used safely for people living with this condition.

The purpose is to determine if this microdose can improve core ADHD symptoms, help with emotional regulation, and enhance sleep.

Participants will receive either the study drug or the placebo each day for a set number of weeks. Throughout the trial, they will attend regular visits where simple questionnaires about attention, mood, and sleep are completed, and a brief blood sample is taken to assess the activity of the enzyme CYP2D6, which helps the body process medicines. Safety checks and brief assessments are performed to monitor any effects.

The purpose of the study is to see whether daridorexant can help improve sleep in people with depression and insomnia, and to check its safety. The study is organized as a double-blind and randomized trial, which means the treatment is assigned by chance and neither the participants nor the study team know which treatment is given during the study. Treatment lasts about 3 months, and sleep and mood are checked during this time to see how the medicine works and whether any side effects occur.

The research involves comparing the effects of the active medication against the placebo to see how it influences both positive and negative symptoms. Positive symptoms refer to behaviors that are added to a person’s experience, such as delusions, while negative symptoms involve a loss of normal functions, such as a lack of emotion or motivation. During the study, doctors will monitor various aspects of health, including physical signs, heart activity through an ECG, and changes in movement or behavior.

Participants will receive either rifaximin or a placebo taken by mouth. During the trial, the focus is on how the treatment affects intestinal barrier integrity, which refers to how well the lining of the intestines prevents harmful substances from leaking into the body. The study also examines inflammatory signalling, which are the chemical messages sent by the body that can cause swelling or irritation in various tissues. Additionally, researchers will look at intestinal permeability, the measure of how easily substances pass through the intestinal wall, and fecal microbiota, which are the types and amounts of bacteria found in the stool.

During the study, participants will take one dose of XPF-010 every day. The process involves monitoring how the body reacts to the medication over an extended period to ensure it is safe for continued use. The study is open-label, meaning that both the researchers and the participants will know which medication is being administered.

During the study, participants may receive either GAMMA-OH or a placebo, which is a substance containing NaCl 0.9% (salt water) with no active medicine. The study uses polysomnography, a method of monitoring sleep through various sensors, to observe different sleep stages such as Rapid Eye Movement (REM) sleep and light sleep. Researchers will also look at how the treatment affects daytime alertness and the need for pain medications like morphine. Additionally, the study monitors for potential side effects, such as bradycardia, which is a slow heart rate, or changes in blood sodium levels.

During the trial, participants are assigned to receive either AP707 or a placebo. The study is double-blind, meaning that neither the participants nor the researchers know which treatment is being given until the end of the study. This is done to ensure that the results are not influenced by expectations. Over a set period, the effectiveness of the treatment will be compared against the placebo to see if there are improvements in symptoms associated with the disorder.

The study compares different treatment approaches. Some participants will receive only the talk therapy, while others will receive the therapy combined with degarelix or a placebo. This research looks at how these different combinations affect behaviors and symptoms over time. Participants will be monitored for a period of time to observe changes in their behavior and physical health.

Participants in this research will be assigned to receive either KarXT or a placebo. This is a randomized study, meaning participants are placed into groups by chance, and it is double-blind, which means neither the participants nor the researchers know which treatment is being given. During the study, the way the medication affects the symptoms of the condition will be observed over a period of several weeks.

Participants in the study will take the medication orally. During the process, the use of music and professional support is evaluated to see how these elements influence the experience and the lasting effects of the treatment. The study monitors how symptoms change from the beginning of the process through a follow-up period of six weeks.

The study is a randomized and double-blind trial, meaning that participants are assigned to groups by chance and neither the individuals nor the medical staff know which specific treatment is being given during the study period. This design helps ensure that the results are based on the actual effects of the medication. Researchers will observe how the medication affects the behavioral and psychological symptoms of the condition over time.

Participants in this study will receive the treatment through a method intended for use in the digestive tract. During the course of the trial, the progress of the symptoms and the physical response to the bacteria will be observed over time.

Participants in the study will be given either hydrocortisone in the form of an oral tablet or a placebo. Following the initial administration of the medication, participants will be monitored over a period of time. This involves completing various questionnaires to report on their experiences and symptoms, as well as providing samples such as saliva. Additionally, some participants may use wearable devices to track their heart rate and heart rate variability, which refers to the variation in time between each heartbeat.

Participants in the study will be assigned to receive either a 20 mg oral capsule of azetukalner or a placebo. The study uses a double-blind method, meaning neither the participants nor the researchers know which treatment is being administered at any given time. This approach helps ensure that the results are not influenced by expectations. During the course of the study, participants will take the assigned capsule once daily.